Aspirin to prevent colon cancer underutilised in high-risk patients

Researchers from Florida Atlantic University's Schmidt College of Medicine have reported that aspirin is underutilised to prevent colorectal cancer as well as recurrent polyps in high risk patients. Their study, ‘Underutilization of aspirin in patients with advanced colorectal polyps,’ was published in The American Journal of Medicine

Colorectal cancer is the third most common cause of cancer deaths in the United States and advanced colorectal polyps are a major risk factor. The US Preventive Services Task Force (USPSTF) concluded that aspirin reduces the risk of colorectal cancer by 40 percent as well as recurrence of advanced polyps. Their guidelines suggest that, without a specific contraindication, health care providers should routinely prescribe aspirin to all patients with advanced colorectal polyps.

To explore whether patients are adhering to these USPSTF recommendations and guidelines, the researchers analysed data from structured interviews on 84 patients, ages 40 to 91 years old, with biopsy proven advanced colorectal polyps between July, 2013 to June 2017. The data showed that only 36 (42.9 percent) of the 84 patients with advanced colorectal polyps reported taking aspirin.

"These data indicate underutilization of aspirin to prevent colorectal cancer as well as recurrent polyps in these high risk patients," said Dr Charles H Hennekens, senior author, the first Sir Richard Doll Professor, and senior academic advisor in FAU's Schmidt College of Medicine.

Co-authors include the first author, Benjamin Fiedler, a senior at Cornell University who has been accepted as a first-year medical student at the Schmidt College of Medicine; Dr Lawrence Fiedler, a gastroenterologist and affiliate associate professor; Dr Michael DeDonno, assistant professor; Dr Kosi Anago, a former internal medicine resident; Leonie de la Cruz, a former medical student; and Dr George R Luck, associate professor, all in FAU's Schmidt College of Medicine.

"These data pose major challenges that require multifactorial approaches by clinicians and their patients," said Benjamin Fiedler. "These approaches should include therapeutic lifestyle changes, adjunctive drug therapies as well as screening."

Therapeutic lifestyle changes of proven benefit include avoiding and treating overweight and obesity as well as regular physical activity and adjunctive drug therapies including aspirin.

"By utilising these multifactorial approaches, we believe that these efforts should achieve the most good for the most patients concerning the prevention as well as screening and early diagnosis and treatment of colorectal cancers," said Hennekens, who has also done ground-breaking research on the benefits of statins, aspirin, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) as well as beta adrenergic blockers - all of which play major roles in decreasing premature deaths from heart attacks and strokes.

Hennekens was the first to demonstrate that aspirin significantly reduces a first heart attack as well as recurrent heart attacks, strokes, and cardiovascular death when given within 24 hours after onset of symptoms of a heart attack as well as to a wide variety of patients who have survived a blockage in the heart, brain or legs. His landmark and first discoveries on aspirin are not limited to cardiovascular disease and include the prevention of recurrent migraine headaches. He also hypothesised from earlier observational study data that aspirin may decrease risks of colorectal cancer and delay cognitive loss as well as reduce the development of type 2 diabetes. Since then, randomized trials and their meta-analyses have indicated that aspirin prevents colorectal polyps as well as colorectal cancer.

"More than 90 percent of patients diagnosed with colorectal cancer are 50 years or older. The major risk factors are similar to those for heart attacks and stroke and include overweight, obesity as well as physical inactivity, a diet low in fibre and high in fat as well as type 2 diabetes," said Fiedler,

According to the US Centers for Disease Control and Prevention, additional risk factors include inflammatory bowel disease such as Crohn's disease or ulcerative colitis; a personal or family history of colorectal cancer or colorectal polyps; and a genetic syndrome such as familial adenomatous polyposis or hereditary non-polyposis colorectal cancer (Lynch syndrome).

Subscribe to our newsletter

Coloproctologynews News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.